The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) In addition, the T-cell responses are especially strong and stable over time, which is also potentially important for activity against these variants.”.

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Conversations in Drug Development Trends

OCTOBER 14, 2024

Scientists now use cutting-edge techniques, including biological therapies that target specific immune system components and precision medicine approaches that personalize treatment plans based on a patient’s genetic profile.

Research 52

Research Clinical Trials Therapies Immune Response 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

The Pharma Data

AUGUST 19, 2021

Interim results from a Phase 1/2a study published in the New England Journal of Medicine also showed that the durability of the immune response was strong, with no waning for at least eight months, the length of time that had been evaluated to date. Source link: [link].

Vaccine 52

Vaccine Immune Response Hospitals FDA 52

The Pharma Data

MARCH 8, 2022

However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. In this way, the viral RNA escapes early recognition by the central antiviral immune-receptor RIG-I. Researchers led by Prof. For example, viral RNAs are masked by the addition of a methyl group.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

JANUARY 25, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

The Pharma Data

JANUARY 5, 2021

” The clinical trial involved 24 COVID patients at one of two Miami-area hospitals who had developed severe acute respiratory distress syndrome, a condition in which the body’s immune response to a serious infection causes the lungs to fill with fluid. The stem cells also sped recovery time.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response. In early April, Nussenzweig’s team began analyzing samples from volunteer survivors who visited The Rockefeller Hospital to donate plasma, which contains the antibodies.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Broad Institute

FEBRUARY 11, 2025

Immunologist Lloyd Bod will take us on a tour of the immune system, and discuss new insights that may help scientists and doctors leverage its cancer-fighting capabilities more effectively.

Medical Schools 52

Medical Schools Immune Response Hospitals Doctors 52

The Pharma Data

NOVEMBER 23, 2021

A team of researchers led by the University of Zurich (UZH) has now discovered another component that contributes to SARS-CoV-2 immunity – previous antibody responses to other, harmless coronaviruses. But even though the protection isn’t absolute, cross-reactive immune responses shorten the infection and reduce its severity.

Immune Response 52

Immune Response Vaccine Virus Hospitals 52

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

Codon

AUGUST 27, 2024

Consider Alice, a 49-year-old woman (and hypothetical patient) who walked into a hospital in Puerto Rico with joint pain, a headache, nausea, and a low fever. While Alice was lucky that her infections were identified at the hospital, it would have been even better had they been identified before she arrived.

DNA 97

DNA Laboratories Hospitals Virus 97

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners. Overall, in-hospital mortality was 12.9

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. government for up to 100,000 doses ( DID, Dec. 28, 2020 ). government for up to 100,000 doses ( DID, Dec. 28, 2020 ).

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

AUGUST 24, 2020

Those infected develop an immune response as their bodies fight off the virus which helps to protect them against it returning. The strongest immune response has been found in the most seriously ill patients. But it is still not clear how strong this protection or immunity is – or how long it lasts.

Virus 52

Virus Immune Response Vaccine Hospitals 52

The Pharma Data

JANUARY 22, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company.

Immune Response 52

Immune Response Clinical Trials Hospitals Trials 52

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Virus 52

Virus Immune Response Disease Clinical Trials 52

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. This is then given to patients, immediately boosting their immune response. The UK Recovery Trial was set up at the start of the pandemic to identify treatments that could help people admitted to hospital with Covid-19. Image copyright.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

PLOS: DNA Science

OCTOBER 3, 2024

The idea to redirect an immune response against a pathogen to fight cancer goes back to 1891, when Manhattan bone surgeon William Coley became intrigued by a man’s neck tumor that melted away after he contracted a nasty Streptococcus skin infection. And every so often, tumors shrank. Writes Edward F.

Vaccine 52

Vaccine Immune Response DNA Treatment 52

The Pharma Data

DECEMBER 9, 2020

In the new study, researchers found that among COVID patients at their safety-net hospital, neurological complications ran the gamut. Safety-net hospitals are obligated, by mandate or mission, to treat people regardless of their ability to pay. In her study group, 10 patients died in the hospital. ” © 2020 HealthDay.

Hospitals 52

Hospitals Doctors Immune Response Virus 52

The Pharma Data

JANUARY 17, 2021

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated. Non-COVID-19-Related.

Immune Response 52

Immune Response Small Molecule Clinical Trials Trials 52

Broad Institute

OCTOBER 4, 2023

This is an unprecedented opportunity to evaluate how immune responses work,” said Robert Manguso , who is co-senior author on the study, an associate member at the Broad, and an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School.

Small Molecule 128

Small Molecule Clinical Trials Engineering Trials 128

Broad Institute

JULY 26, 2022

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. muciniphila ’s cell membrane. That discovery was quite surprising.

Research 52

Research Immune Response Medical Schools Disease 52

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

JUNE 2, 2022

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. Applicability of the technology has also been demonstrated for additional infectious disease pathogens, including those that cause hospital-acquired infections.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MAY 31, 2022

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. Applicability of the technology has also been demonstrated for additional infectious disease pathogens, including those that cause hospital-acquired infections.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

JANUARY 11, 2021

Bin Cao, from the National Center for Respiratory Medicine at the China-Japan Friendship Hospital and Capital Medical University, both in Beijing. And he’s seen similar issues among patients at his hospital. ” The Wuhan study also tried to track survivors’ longer-term immunity against COVID-19. .”

Hospitals 52

Hospitals Virus Vaccine Immune Response 52

The Pharma Data

JULY 8, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Pharmaceutical Companies Disease 52

The Pharma Data

DECEMBER 8, 2020

In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials. Sinopharm’s vaccine was developed from a SARS-CoV-2 strain isolated from a patient in the Jinyintan Hospital, Wuhan. The vaccine was also demonstrating a strong safety profile.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

AUGUST 9, 2021

Dr Munir said: “Our studies demonstrate that induction of a local immune response at the point of entry of SARS-CoV-2 has the potential to not only limit clinical disease, but also – and perhaps even more importantly – virus transmission from infected to uninfected individuals.”

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

OCTOBER 18, 2020

Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. Hospitals interested in participating in the study should contact info@edesabiotech.com or visit www.clinicaltrials.gov (Identifier: NCT04401475).

Immune Response 40

Immune Response Hospitals Treatment Virus 40

The Pharma Data

JANUARY 4, 2021

Data from Moderna’s trials showed that people between 18 and 55 who received two 50-microgram doses had an “identical immune response” to the standard of two 100-microgram doses, Dr. Moncef Slaoui explained, the Times reported. But a faster-spreading virus could swamp hospitals with seriously ill patients.

Vaccine 52

Vaccine Immune Response Virus Hospitals 52